Prognostic Role of bcl-2 Rearrangement in Follicular Lymphoma
Author Information
Author(s): F Bertoni, G Bosshard, E Roggero, E Ceresa, F Cavalli, E Zucca
Primary Institution: Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland
Hypothesis
Does the detection of bcl-2(MBR)/JH rearrangement in peripheral blood predict outcomes in patients with follicular lymphoma?
Conclusion
The detection of bcl-2/JH rearrangement at diagnosis is not a prognostic factor in follicular lymphoma, but clearance of these cells post-treatment correlates with better overall survival.
Supporting Evidence
- 35 of 59 patients were bcl-2/JH positive at diagnosis.
- Clearance of bcl-2/JH-positive cells correlated with better overall survival.
- 82% of patients who were bcl-2/JH positive at diagnosis became negative post-treatment.
Takeaway
This study looked at blood tests for a specific gene change in lymphoma patients. It found that while the gene change at diagnosis doesn't help predict how long patients will live, getting rid of it after treatment is a good sign.
Methodology
Peripheral blood samples were analyzed for bcl-2(MBR)/JH rearrangement using PCR in 59 patients with follicular lymphoma.
Limitations
The study's findings may not be generalizable due to the specific patient population and the need for longer follow-up.
Participant Demographics
Patients were HIV-negative and histologically diagnosed with follicular lymphoma.
Statistical Information
P-Value
P < 0.0001 for ECOG PS > 1 associated with reduced OS
Confidence Interval
95% CI 68-91%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website